The Department of Defense temporary halted the sales of products containing 1,3-dimethylamylamine (DMAA) within military facilities after recent reports showed two soldier deaths and additional adverse health effects in other service members may be related to use of the dietary supplements.
The Department of Defense's moratorium will remain in effect
pending further review of relevant scientific evidence and reported
The Assistant Secretary of Defense for Health Affairs Jonathan
Woodson asked the surgeons general of the military services to conduct a
review of available scientific evidence and adverse event reports
(AERs) to better understand any potential relationship between DMAA and
DMAA has been cited in a class action lawsuit claims bodybuilding and supplements from Florida-based BPI Sports contained
undisclosed 1,3-dimethylamylamine (DMAA), an amphetamine-like
ingredient that poses a serious health risk and has potentially
life-threatening side effects, according to the suit.
The plaintiffs seek restitution and class damages for consumer
law violations, unfair competition, false and misleading advertising,
breach of express warranty and breach of implied warranty.
DMAA is banned by several athletic organizations, including the
World Anti-Doping Agency and Major League Baseball. It is illegal to
sell in many countries, including Canada and New Zealand. The lawsuit
says the ingredient is supposedly derived from the oil of the geranium
plant. DMAA, also known as Methylhexanamine and Geranainine, is a
vasoconstrictor and central nervous system stimulant.